Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4941 - Outcomes of Adjuvant Chemotherapy for Stage II and III Colorectal Cancer in Korea, 2011-2014: A Nationwide Study Based on the database of Quality Assessment and the Health Insurance


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


In Gyu Hwang


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


I.G. Hwang1, J.S. Lee2, S. Lee3, S.K. Baek4, J.G. Kim5, T.W. Kim6

Author affiliations

  • 1 Internal Medicine, Chung-Ang University College of Division of Hemato-Oncology Medicine, 156-861 - Seoul/KR
  • 2 Statistics, Asan Medical Center, Seoul/KR
  • 3 Internal Medicine, Soonchunhyang University Hospital Cheonan, Cheonan/KR
  • 4 Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, 130-702 - Seoul/KR
  • 5 Department Of Oncology/hematology, Kyungpook National University Medical Center, Daegu/KR
  • 6 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR


Abstract 4941


Few population-based analyses on treatment outcomes of colorectal cancer (CRC) have been conducted in Asian countries. We conducted a nationwide study to assess the outcomes of adjuvant chemotherapy (AC) for patients with stage II and III CRC in South Korea.


Data from the Health Insurance Review and Assessment Service Database (HIRA) were analyzed for demographics, tumor characteristics, adjuvant chemotherapy, and survival of patients who underwent curative-intent surgical resection for CRC from 2011 to 2014.


From the HIRA data, a total of 61315 patients were identified: 15620 (25.5%) in stage I, 20525 (33.5%) in Stage II, and 25170 (41.0%) in stage III. Chemotherapy regimens were consisted: 11332 (18.5%) in 5-fluorouraci plus leucovorin or capecitabine (FL/CAP), 13183 (21.5%) in FL/CAP with oxaliplatin (FOLFOX/CAPOX), 357 (0.6%) in uracil and tegafur/doxifluridine (UFT/D) and 36443 (59.4%) in surgery alone. For the patients with stage II colorectal cancer, the adjuvant chemotherapy was associated with a significant increase in survival rate (FL/CAP: hazard ratio [HR], 0.44; 95% CI, 0.40-0.50, and FOLFOX/CAPOX: HR, 0.48; 95% CI, 0.41-0.55, respectively), however UFT/D regimens were not statistically significant. In the patients with stage III, the adjuvant chemotherapy was significantly effective for survival rate (FL/CAP: HR, 0.43; 95% CI, 0.40-0.47, FOLFOX/CAPOX: HR, 0.38; 95% CI, 0.36-0.41, respectively), UFT/D were also not statistically effective.


Adjuvant chemotherapy with FL/CAP and FOLFOX/CAPOX showed a survival benefit for patients with stage II and III colorectal cancer.

Clinical trial identification

Legal entity responsible for the study

In Gyu Hwang




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.